Dupont Capital Management Corp Takes $199,000 Position in Clorox Company (The) (CLX)

Dupont Capital Management Corp purchased a new position in Clorox Company (The) (NYSE:CLX) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 1,505 shares of the company’s stock, valued at approximately $199,000.

A number of other hedge funds have also recently modified their holdings of the stock. Andra AP fonden grew its stake in Clorox Company (The) by 4.8% in the third quarter. Andra AP fonden now owns 169,084 shares of the company’s stock worth $22,304,000 after purchasing an additional 7,784 shares during the period. Villere ST Denis J & Co. LLC bought a new stake in Clorox Company (The) in the third quarter worth $450,000. Palisade Capital Management LLC NJ bought a new stake in Clorox Company (The) in the third quarter worth $221,000. Berkshire Asset Management LLC PA bought a new stake in Clorox Company (The) in the third quarter worth $237,000. Finally, Crossvault Capital Management LLC boosted its holdings in Clorox Company (The) by 2.9% in the third quarter. Crossvault Capital Management LLC now owns 35,759 shares of the company’s stock worth $4,717,000 after acquiring an additional 1,000 shares in the last quarter. 71.58% of the stock is currently owned by institutional investors.

Several research firms have commented on CLX. BMO Capital Markets reissued an “outperform” rating on shares of Clorox Company (The) in a report on Tuesday, September 12th. Jefferies Group LLC reissued a “hold” rating and issued a $137.00 target price (up from $136.00) on shares of Clorox Company (The) in a report on Wednesday, August 9th. Barclays PLC reissued an “equal weight” rating and issued a $136.00 target price (down from $140.00) on shares of Clorox Company (The) in a report on Friday, August 4th. BidaskClub raised Clorox Company (The) from a “strong sell” rating to a “sell” rating in a report on Monday, July 31st. Finally, Royal Bank Of Canada reissued a “hold” rating and issued a $115.00 target price on shares of Clorox Company (The) in a report on Wednesday, August 2nd. Two analysts have rated the stock with a sell rating, ten have issued a hold rating and three have given a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $128.72.

Clorox Company (CLX) opened at $135.08 on Tuesday. The stock has a market capitalization of $17,026.34, a price-to-earnings ratio of 23.79, a PEG ratio of 3.60 and a beta of 0.39. The company has a current ratio of 1.10, a quick ratio of 0.77 and a debt-to-equity ratio of 3.02. Clorox Company has a 1-year low of $112.15 and a 1-year high of $141.76.

Clorox Company (The) (NYSE:CLX) last announced its quarterly earnings results on Wednesday, November 1st. The company reported $1.46 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.41 by $0.05. The firm had revenue of $1.50 billion for the quarter, compared to the consensus estimate of $1.48 billion. Clorox Company (The) had a return on equity of 161.59% and a net margin of 11.84%. The company’s quarterly revenue was up 4.0% on a year-over-year basis. During the same period in the prior year, the company posted $1.36 earnings per share. analysts predict that Clorox Company will post 5.58 EPS for the current year.

The firm also recently declared a quarterly dividend, which was paid on Monday, November 13th. Stockholders of record on Wednesday, October 25th were issued a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.49%. The ex-dividend date of this dividend was Tuesday, October 24th. Clorox Company (The)’s payout ratio is currently 61.88%.

In other Clorox Company (The) news, SVP Matthew T. Laszlo sold 20,051 shares of the stock in a transaction dated Wednesday, November 8th. The stock was sold at an average price of $130.46, for a total value of $2,615,853.46. Following the transaction, the senior vice president now owns 10,896 shares of the company’s stock, valued at $1,421,492.16. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP James E. Foster sold 9,861 shares of the stock in a transaction dated Wednesday, August 23rd. The shares were sold at an average price of $138.51, for a total value of $1,365,847.11. Following the completion of the transaction, the executive vice president now directly owns 22,069 shares in the company, valued at approximately $3,056,777.19. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 41,293 shares of company stock worth $5,560,303. Corporate insiders own 1.00% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This news story was posted by Markets Daily and is the sole property of of Markets Daily. If you are reading this news story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be read at https://www.themarketsdaily.com/2017/11/14/dupont-capital-management-corp-takes-199000-position-in-clorox-company-the-clx.html.

About Clorox Company (The)

The Clorox Company is a manufacturer and marketer of consumer and professional products. The Company sells its products primarily through mass retail outlets, e-commerce channels, wholesale distributors and medical supply distributors. The Company operates through four segments: Cleaning, Household, Lifestyle and International.

Want to see what other hedge funds are holding CLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Clorox Company (The) (NYSE:CLX).

Institutional Ownership by Quarter for Clorox Company (The) (NYSE:CLX)

Receive News & Ratings for Clorox Company (The) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clorox Company (The) and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply